LATTANZIO, STEFANO
 Distribuzione geografica
Continente #
NA - Nord America 1.174
EU - Europa 1.049
AS - Asia 522
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 1
Totale 2.750
Nazione #
US - Stati Uniti d'America 1.173
CN - Cina 269
UA - Ucraina 215
IE - Irlanda 191
TR - Turchia 185
SE - Svezia 169
FR - Francia 145
GB - Regno Unito 138
DE - Germania 69
IT - Italia 67
IN - India 62
FI - Finlandia 45
RU - Federazione Russa 4
EU - Europa 3
VN - Vietnam 3
PL - Polonia 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
CA - Canada 1
CL - Cile 1
IL - Israele 1
IR - Iran 1
JP - Giappone 1
MT - Malta 1
Totale 2.750
Città #
Chandler 262
Jacksonville 257
Dublin 191
Southend 132
Izmir 100
Dearborn 88
Princeton 85
Ashburn 72
Nanjing 70
Beijing 60
Wilmington 49
Cambridge 43
Altamura 26
Nanchang 24
Kunming 17
Washington 14
Hebei 13
Ann Arbor 12
Shenyang 12
Boardman 11
Jiaxing 11
Woodbridge 11
Augusta 10
Changsha 10
Grevenbroich 8
New York 8
Norwalk 8
San Mateo 8
Chieti 7
Hangzhou 7
Tianjin 7
Falls Church 6
Hefei 4
Jinan 4
Lanzhou 4
Los Angeles 4
Mountain View 4
Ningbo 4
Seattle 4
Tappahannock 4
Chongqing 3
Dong Ket 3
Milan 3
Rome 3
Boscotrecase 2
Cepagatti 2
Changchun 2
Chaoyang 2
Düsseldorf 2
Helsinki 2
Leawood 2
Shanghai 2
Simi Valley 2
Bangalore 1
Bellante 1
Catania 1
Dallas 1
Durham 1
Fairfield 1
Fuzhou 1
Greifswald 1
Haikou 1
Houston 1
Hunedoara 1
Kraków 1
London 1
Louisville 1
Melita 1
Monmouth Junction 1
Newcastle Upon Tyne 1
Newcastle upon Tyne 1
Novokuznetsk 1
Orange 1
Qingdao 1
Quzhou 1
San Francisco 1
San Giacomo degli Schiavoni 1
San Nicola la Strada 1
Secaucus 1
Taizhou 1
Tokyo 1
Torino 1
Toronto 1
Vancouver 1
Villa Bartolomea 1
Walnut 1
Wuhan 1
Zgierz 1
Zhengzhou 1
Ürümqi 1
Totale 1.738
Nome #
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus 105
Pentraxin 3 and platelet activation in obese patients after gastric banding 104
Soluble CD40L in Mediterranean Spotted Fever: relation to oxidative stress and platelet activation 101
Variability in the Recovery Rate of Platelet Cyclooxygenase Activity During Chronic Therapy With Low-Dose Aspirin in Type 2 Diabetes. 98
Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. 87
The Recovery of Platelet Cyclooxygenase Activity Explains Interindividual Variability in Responsiveness to Low-Dose Aspirin in Patients With and Without Diabetes. 86
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 84
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. implications for aspirin 'resistance'. 81
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". 80
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. 78
Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. 76
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. 74
Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease 74
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 73
Postprandial hyperglycemia is an important determinant of platelet activation. evidence from biochemical measurements and pharmacological intervention with acarbose 73
LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro 73
Circulating endothelial progenitor cells and low-dose-aspirin-insensitive thromboxane biosynthesis in polycythemia rubra vera. 70
Circulating Myeloid-Related Protein-8/14 is Related to Thromboxane-Dependent Platelet Activation in Patients With Acute Coronary Syndrome, With and Without Ongoing Low-Dose Aspirin Treatment. 69
Effects of high-amount-high-intensity exercise on in vivo platelet activation: Modulation by lipid peroxidation and AGE/RAGE axis 68
Postprandial hyperglycemia is an important determinant of platelet activation in early type 2 diabetes mellitus. Evidence from biochemical measurements and pharmacological intervention with acarbose. 67
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. 67
Endogenous Secretory RAGE in Obese Women: Association with Platelet Activation and Oxidative Stress 67
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 66
Ultrarush venom immunotherapy and the lipoxin a4 inflammation resolution pathway 66
Determinants of the Variability in the Recovery Rate of Platelet Cyclooxygenase Activity during Chronic Therapy with Low-Dose Aspirin in Type 2 Diabetes 64
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. 62
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 62
Effects of Acarbose on in Vivo Markers of Oxidative Stress and Platelet Activation in Early Type 2 Diabetes. 61
Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low-HDL Phenotype 58
Determinants of Platelet Activation in Heart Failure. 56
Endogenous secretory rage in obese women: association with oxidative stress and platelet activation. Proc. 112° Congr. Naz. Soc It. Med. Interna, Roma, ottobre 2011, Int Emerg Med 6(S2): S186, 2011 56
Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge and in vivo urinary thromboxane production in healthy male subjects. 55
Effects of Acarbose on in Vivo Markers of Oxidative Stress and Platelet Activation in Early Type 2 Diabetes 55
Soluble CD40L in Mediterranean Spotted Fever: Relation to oxidative stress and platelet activation. 55
Soluble CD40L as an indicator of platelet Activation in Heart Failure 52
Determinants of Platelet Activation in Heart Failure. 52
Oxidative Stress and Platelet Activation in Subjects with Moderate Hyperhomocysteinemia Due to MTHFR 677 C->T Polymorphism. 48
Oxidative Stress and Platelet Activation in Subjects with Moderate Hyperhomocysteinemia Due to MTHFR 677 C->T Polymorphism 48
Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the “Low-HDL” Phenotype. 46
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 46
Determinants of Thromboxane-Dependent Platelet Activation in Heart Failure. 46
Oxidative Stress and Platelet Activation in Subjects with Moderate Hyperhomocysteinemia Due to MTHFR 677 C->T Polymorphism. 43
Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the “Low-HDL” Phenotype 41
Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation 11
Totale 2.904
Categoria #
all - tutte 9.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.081


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019112 0 0 0 0 0 0 0 0 0 0 4 108
2019/2020677 186 44 1 3 66 49 90 80 12 81 62 3
2020/2021269 44 4 45 0 10 59 6 8 42 43 3 5
2021/2022209 3 7 2 58 20 6 2 14 17 10 22 48
2022/2023655 46 97 46 67 64 127 33 45 101 7 9 13
2023/2024286 29 10 22 7 19 97 73 11 14 4 0 0
Totale 2.904